

**TO**

Hospital Providers, HMOs and Other Managed Care Programs

REGARDING

New COVID-19-Related Procedure Codes for Inpatient Hospital Claims

New COVID-19-Related Procedure Codes for Inpatient Hospital Claims

For dates of service on and after April 1, 2022, ForwardHealth will accept and process claims for the following procedure codes. These codes describe COVID-19 vaccination and treatment in inpatient hospital settings.

| CODE | DESCRIPTION |
|---------|---|
| XW013V7 | Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 |
| XW013W7 | Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 |
| XW023V7 | Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7 |
| XW023W7 | Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7 |
| XW023X7 | Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 |
| XW023Y7 | Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7 |
| XW0DXR7 | Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7 |
| XW0G7R7 | Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7 |
| XW0H7R7 | Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7 |

